Huya, Eisai strike deal for Chipscreen drug

Huya Bioscience International LLC (San Diego, Calif.) granted Eisai Co. Ltd. (Tokyo:4523) exclusive rights to HBI-8000 in several Asian territories. Huya has ex-China rights to the drug from Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, China), which markets the drug in China as Epidaza chidamide to treat relapsed or refractory peripheral T cell lymphoma (PTCL).

Huya did not respond to an inquiry concerning the development phase in Japan of the small molecule histone deacetylase ( HDAC) inhibitor. ...